To access the call, call 877-303-9226 (national) or 409-981-0870 (international) and provide convention ID 1081289. A live web stream of the presentation will be held on the Investors and Media segment of Mersana’s online page on www.mersana.com.
About Mersana Therapeutics Mersana Therapeutics is a clinically stage biopharmaceutical company that uses its differentiated and patented ADC platforms to expand new CDS with optimal efficacy, protection and tolerability to improve the lives of others battling cancer. Mersana’s main candidate product, XMT-1536, is in the extension portion of a Phase 1 clinical proof-of-concept test exam in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana’s at the time ADC candidate product targeting tumors expressing NaPi2b, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is a component of the dose accumulation portion of a proof-of-concept phase 1 clinical trial. The company’s startup systems come with an ADC aimed at B7-H4, as well as an ADC STING agonist developed using the company’s Immunosynthen platform. In addition, several components are using Mersana’s Dolaflexin platform to advance their ADC pipelines.
Contact: